Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1Phase 1 1

Status

Completed 55Recruiting 51Active not recruiting 34Terminated 23Unknown 7Not yet recruiting 5Withdrawn 4Enrolling by invitation 1Available 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 4

Sponsor

Cancer Type

Breast 4CNS 1

Conditions

Breast Neoplasms 3HER2 Negative Breast Cancer Not Immediately Operated 1Brain Neoplasms 1

Interventions

Cyclophosphamide 129Cisplatin 119Radiotherapy 115pembrolizumab 111Carboplatin 97Paclitaxel 96Gemcitabine 96Magnetic Resonance Spectroscopy 80Nivolumab 76Bevacizumab 76Fluorouracil 74Dexamethasone 73Radiosurgery 66Docetaxel 59Rituximab 58Leucovorin 57Oxaliplatin 55Capecitabine 55Biopsy 53Doxorubicin 52fludarabine 51Drug Therapy 45durvalumab 44Cytarabine 44Etoposide 42fludarabine phosphate 40Pemetrexed 40Radiation 39atezolizumab 36Surveys and Questionnaires 36

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Withdrawn × ribociclib × Clear all
NCT05664893 2026-04-15

CALHYS

Centre Antoine Lacassagne

Phase 1/2 Withdrawn
Breast

HER2 Negative Breast Cancer Not Immediately Operated

NCT06585969 2026-02-12

DISCORDANT

Danish Breast Cancer Cooperative Group

Phase 3 Withdrawn
Breast

Breast Neoplasms

NCT04585724 2021-10-18

Stereotactic Radiosurgery With Abemaciclib, Ribociclib, or Palbociclib in Treating Patients With Hormone Receptor Positive Breast Cancer With Brain Metastases

Emory University

Phase 1 Withdrawn
BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT03081234 2018-03-15

EarLEE-2

Novartis

Phase 3 Withdrawn
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡